Antithyroid drug-induced agranulocytosis: experience of the French Centers of Pharmacovigilance with a retrospective study of more than 200 cases

E. Andrès¹*, T. Weitten¹, M. Alt-Tebacher²

et le réseau français des Centres Régionaux de Pharmacovigilance (CRPV)

(V. Gras-Champel - CRPV Amiens; D. Bourneau-Martin - CRPV Angers; M.B. Valnet Rabier - CRPV Besançon; H. Geniaux - CRPV Bordeaux; D. Carlhant - CRPV Brest; S. Fedrizzi - CRPV Caen; C. Chenaf - CRPV Clermont-Ferrand; A. Disson-Dautriche - CRPV Dijon; S. Logerot - CRPV Grenoble; M. Auffret - CRPV Lille; M.L. La Roche - CRPV Limoges; T. Vial - CRPV Lyon; M.J. Jean-Pastor - CRPV Marseille; C. Peciaux - CRPV Montpellier; N. Bornert-Keller - CRPV Nancy; P. Jolliet - CRPV Nantes; B. Baldin - CRPV Nice; C. Picard - CRPV Rennes; N. Massy - CRPV Rouen; M.N. Beyens - CRPV Ste Etienne; C. Muller - CRPV Strasbourg; D. Abadie - CRPV Toulouse; A.P. Jonville-Bera - CRPV Tours)

¹ Service de Médecine Interne, Clinique Médicale B, CHRU de Strasbourg; ² CRPV de STRASBOURG

OBJECTIVE

Agranulocytosis to the antithyroid drugs is a rare adverse drug effect exposure to potentially lethal infections. It is a public health problem with hyperthyroidism in nearly 1% of the French population. However, many uncertainties remain in the knowledge, understanding, prevention and management of this drug effect.

In this work, we report the French experience through pharmacovigilance data

RESULTS

This study is one of the largest series ever collected on antithyroid drug-induced agranulocytosis. It primarily concerns carbimazol, leader antithyroid drug used in France. It was noted an almost bimodal distribution with women over 65, but also young women aged 20-35 years. This distribution was explained by the fact that the majority of patients treated with antithyroid drug have Graves’ disease.

Often nonspecific clinical presentations and low contribution of microbiological investigations highlight the difficulties of management. This adverse drug exposed to the often serious infectious complications and death in 8 % of cases.

Duration of agranulocytosis, neutropenia and hospitalization are very close if not superior in the group treated with G-CSF. Univariate analyzes showed no statistically significant association between the use of G-CSF and duration of agranulocytosis. Mortality was not statistically significant decreased in the G-CSF group: 4.6% versus 12.9%.

CONCLUSION

The data of this work and a critical review of the literature lead to useful practical recommendations for the prevention and the diagnostic and therapeutic management of this adverse drug effect.

Allocated Poster Number: P1042

¹ : emmanuel.andres@chru-strasbourg.fr